Department of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Secretary Xavier Becerra announced Monday that he has ordered Medicare to "reassess" the agency's 2022 premium rate hike for Medicare Part B, citing Biogen's move to slash the price of its costly new Alzheimer's drug – which was blamed for a hefty portion of the premium increase that impacts tens of millions of Americans.
Health and Human Services Secretary Xavier Becerra speaks in the East Room of the White House in Washington, D.C., on December 1, 2021. "Today I’m instructing the Centers for Medicare and Medicaid Services to reassess the recommendation for the 2022 Medicare Part B premium, given the dramatic price change of the Alzheimer’s drug, Aduhelm," Becerra said in a statement. "With the 50% price drop of Aduhelm on January 1, there is a compelling basis for CMS to reexamine the previous recommendation."
A CMS spokesperson told FOX Business that the agency "is reviewing the Secretary's statement to determine next steps."
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Medicare Told to Reassess Premium Hike for Alzheimer's DrugU.S. health secretary Xavier Becerra is ordering Medicare to reassess a big premium increase facing millions of seniors this year
Les mer »
Medicare told to reassess premium hike for Alzheimer's drugHealth secretary orders Medicare to reassess a big premium increase facing millions of seniors this year, attributed in large part to a pricey new Alzheimer's drug with questionable benefits.
Les mer »
Government May Scale Back Medicare Part B Premium IncreaseMedicare officials were instructed Monday to reassess the standard monthly amount due to a reduction in the cost of a drug that caused half the premium jump.
Les mer »
Medicare is about to make its most important coverage decision in years. Here’s how people with Alzheimer’s and others might be affected.A controversial new drug is roiling the medical community and driving up Medicare premiums.
Les mer »
Goldman Sachs names Tesla a top stock pick for 2022, hikes price targetElectric vehicle innovation will continue to drive growth for investors in 2022, according to Goldman Sachs.
Les mer »
Thousands arrested in Kazakhstan since riots erupted a week agoKazakhstan authorities arrest over 5,000 people for questioning as part of 125 separate investigations into the unrest that has caused millions of damage to property
Les mer »